Results 51 to 60 of about 53,515 (238)

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

open access: yesOncoImmunology, 2018
Introduction: Checkpoint inhibitors, including the CTLA-4 blocking antibody ipilimumab, have become the new standard therapy for many metastatic cancers.
Anders H. Kverneland   +5 more
doaj   +1 more source

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

open access: yesCase Reports in Oncology, 2018
Simultaneous or sequential, planned administration of ipilimumab could significantly enhance the antitumor effects of nivolumab in advanced melanoma patients.
Taku Fujimura   +8 more
doaj   +1 more source

ROS Self‐Supply Nanoplatform Based on Fenton Catalyst for Chemodynamic and Immunotherapy: Reprogramming Cold Tumor Into Hot Tumor in Cancer Treatment

open access: yesAdvanced Science, EarlyView.
A multifunctional HA‐conjugated nanoplatform (HA‐PGMC) integrates CuO2, glucose oxidase, and mil‐100 to enable cascade catalytic ROS generation in tumor microenvironments. This self‐supplying ROS strategy induces immunogenic cell death, reprograms “cold” tumors into “hot” ones, and synergizes with PD‐L1 blockade, achieving potent chemodynamic ...
Man Lung Lee   +6 more
wiley   +1 more source

Real world treatment sequences and outcomes for metastatic renal cell carcinoma.

open access: yesPLoS ONE, 2023
ObjectivesThe treatment landscape for metastatic renal cell carcinoma changed a lot in the last few years. This study aimed to assess the treatment sequences and outcomes for metastatic renal cell carcinoma in a real-world setting.Materials and methodsWe
Gu-Shun Lai   +8 more
doaj   +1 more source

Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation

open access: yesAdvanced Science, EarlyView.
BNC2 exhibits context‐dependent opposing functions across multiple cancer types. This study reveals BNC2 as an oncogenic driver of melanoma proliferation and metastasis through transcriptional activation of PIK3CA. The natural compound TSN simultaneously degrades BNC2 and its oncogenic partner SMAD3 via CRBN‐dependent ubiquitination.
Hui Dai   +7 more
wiley   +1 more source

Spatial Transcriptomics Reveals a T Cell‐Mediated Microglial Activation Axis of Immune Checkpoint Inhibition‐Related Adverse Events in the Brain

open access: yesAdvanced Science, EarlyView.
Immune checkpoint inhibition (ICI) reshapes the hippocampal neuroimmune niche. Spatial transcriptomic profiling and human brain histological analyses identify neuroinflammation and altered neuronal and glial programs. Notably, T cell depletion prevents ICI‐driven microglial activation, establishing the T cell–microglia crosstalk axis as a driving ...
Devyani Swami   +7 more
wiley   +1 more source

A Dual‐Delivery System Designed to Overcome EV‐Mediated Ferroptosis Resistance for Efficient Solid Tumor Therapy

open access: yesAdvanced Science, EarlyView.
(A) Establishment and characterization of the osteosarcoma‐targeted dual‐delivery nanoplatform mBAP1/siENO1@LNP‐OTP for simultaneous regulation of BAP1 and ENO1 in tumor cells. (B) After intravenous administration, mBAP1/siENO1@LNP‐OTP preferentially accumulates at tumor sites through OTP‐mediated targeting.
Yechao Shen   +13 more
wiley   +1 more source

Can Chemoradiotherapy Expand Immune Checkpoint Blockade Responsiveness in Mismatch Repair‐Proficient Rectal Cancer?

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Immune checkpoint blockade (ICB) has transformed the treatment of mismatch repair‐deficient (dMMR) colorectal cancer but produces no meaningful benefit in advanced mismatch repair‐proficient (pMMR) disease. In the neoadjuvant setting, however, pathological responses have been reported in a subset of pMMR tumors, suggesting that clinical ...
Kimihiro Yamashita   +4 more
wiley   +1 more source

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data

open access: yesDiagnostics, 2018
Recent studies suggest that combining nivolumab with ipilimumab is a more effective treatment for melanoma patients, compared to using ipilimumab or nivolumab alone.
Theodoros G. Soldatos   +4 more
doaj   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy